It is evident from the above findings that STAT3 plays an important role in immunosuppression by regulating the expression of the immune checkpoint protein PD-L1 in both cancer and immune cells and may be a promising therapeutic target that can be modulated in order to overcome resistance to and enhance the efficacy of immune checkpoint inhibitors in NSCLC. This evidence concerns the gene CD274 and cancer.